根据向美国证券交易委员会（SEC）提交的文件，生物制药公司ArriVent BioPharma Inc.已签订一项公开市场销售协议。依据该协议，公司可不时发行并销售其普通股，总金额最高可达2.5亿美元。
此项安排为公司提供了灵活的融资渠道，使其能够根据市场状况和自身资金需求，选择性地向公开市场发行新股。销售所得款项将用于一般公司用途，可能包括营运资金、研发投入以及其他战略投资。
通过此类协议，上市公司能够更高效地筹集资金，同时为市场提供持续的股票供应。协议的签署标志着ArriVent BioPharma在资本运作方面迈出了新的一步，旨在支持其未来的业务发展与管线推进。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.